OTC · Medical - Devices

Lumos Diagnostics Holdings Ltd. (LDXHF) Stock

$0.08 +8.70% OTC: LDXHF Healthcare

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19.

Valuation

MetricValue
Price$0.08
Market Cap$57.25M
P/E Ratio-5.76
P/B Ratio10.37
P/S Ratio4.35
EPS (TTM)$-0.01
52-Week High$0.24
52-Week Low$0.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-164.12%
ROA-44.27%
ROCE-94.66%
Gross Margin2.96%
Operating Margin-81.50%
Net Margin-75.84%
Debt/Equity2.26
Current Ratio0.73

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$12.0M$11.0M$11.0M$13.0M
Operating Profit$-11.0M$-24.0M$-7.0M$-7.0M$-8.0M
Net Profit$-15.0M$-46.0M$-9.0M$-9.0M$-7.0M
EPS$-0.09$-0.30$-0.04$-0.02$-0.01
Op Margin-58.4%-205.4%-62.3%-64.0%-62.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$98.0M$37.0M$25.0M$27.0M$21.0M
Total Liabilities$40.0M$19.0M$16.0M$20.0M$15.0M
Cash$45.0M$8.0M$3.0M$6.0M$2.0M
Borrowings$8.0M$7.0M$10.0M$8.0M$7.0M

Latest News

Lumos Diagnostics secures US$768,000 FebriDx order as US commercial rollout gathers pace Proactive · Aug 4, 2026 Lumos Diagnostics expands FebriDx reach into Romania through Alpha Medical distribution deal Proactive · Jul 30, 2026 Lumos Diagnostics caps FY26 with FebriDx revenue up 875% and US rollout gaining momentum Proactive · Jul 27, 2026 Lumos Diagnostics secures 30-site FebriDx rollout across major US urgent care networks Proactive · Jul 21, 2026 Lumos Diagnostics receives A$710,000 R&D tax rebate to support point-of-care technology development Proactive · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-17.0M$-10.0M$1.0M$-9.0M
Investing Cash Flow$-14.0M$-9.0M$4.0M$0$0
Financing Cash Flow$47.0M$0$0$-1.0M$-1.0M
Net Cash Flow$44.0M$-37.0M$-5.0M$3.0M$-5.0M
Free Cash Flow$-17.0M$-22.0M$-10.0M$1.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.20
EV / EBITDA-6.73
FCF Yield-4.60%
Quick Ratio0.63
Interest Coverage-9.53
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held20.17%
Institutions Held18.99%
Institutions Float Held23.78%
Institutional HolderSharesReport Date
Ethos Financial Group, LLC 12,5002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.

Lumos Diagnostics Holdings Ltd. is headquartered in US.

Lumos Diagnostics Holdings Ltd. (LDXHF) stock trades at $0.08 with a market capitalization of $57.25M. The stock is valued at a price-to-earnings (P/E) ratio of -5.76, price-to-book of 10.37, price-to-sales of 4.35. Over the past 52 weeks the stock has ranged between $0.06 and $0.24, and currently trades 66.7% below its 52-week high.

On profitability, Lumos Diagnostics Holdings Ltd. generates a return on equity (ROE) of -164.12%, return on capital employed of -94.66%, an operating margin of -81.50%, a net profit margin of -75.84%.

Official website: lumosdiagnostics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides